Jeremie Calais (@calaisjeremie) 's Twitter Profile
Jeremie Calais

@calaisjeremie

Nuclear medicine and theranostics at UCLA
@UCLA @UCLAJCCC @UCLATheranostic
@UCLAnewsroom @UCLAHealth
#PETCT #nuclearmedicine #theranostics

ID: 1317210197765484546

calendar_today16-10-2020 21:06:18

662 Tweet

1,1K Followers

203 Following

Michael Hofman (@drmhofman) 's Twitter Profile Photo

Twenty cycles (that's right 20) of Lutetium-177 PSMA-617 for metastatic castration-resistant cancer!! Check our case report just published in JNM jnm.snmjournals.org/content/early/… Current randomized controlled data demonstrate the safety and efficacy of 6 cycles of

PSMA and Beyond Conference (@psmaconference) 's Twitter Profile Photo

ONE WEEK until the 2025 PSMA & Beyond Conference! Space is limited so register soon! If you cannot join us in LA, virtual registration is available for only $50! bit.ly/psmabeyond

ONE WEEK until the 2025 PSMA & Beyond Conference! Space is limited so register soon! If you cannot join us in LA, virtual registration is available for only $50! bit.ly/psmabeyond
Jeremie Calais (@calaisjeremie) 's Twitter Profile Photo

Kinetics of PSMA PET signal after radiotherapy in 217 prostate cancer lesions: It takes multiple months for the uptake to decrease (> 6 months). Beware of "pseudo-progression" on PSMA PET performed shortly after RT. Radiotherapy & Oncology Masatoshi Hotta UCLA sciencedirect.com/science/articl…

Kinetics of PSMA PET signal after radiotherapy in 217 prostate cancer lesions: It takes multiple months for the uptake to decrease (&gt; 6 months). Beware of "pseudo-progression" on PSMA PET performed shortly after RT. <a href="/RO_GreenJournal/">Radiotherapy & Oncology</a> <a href="/masatoshihotta/">Masatoshi Hotta</a> <a href="/UCLA/">UCLA</a> 
sciencedirect.com/science/articl…
Michael Hofman (@drmhofman) 's Twitter Profile Photo

... how common is PSMA-negative significant prostate cancer? In the proPSMA study it was 3.3% Hot of the press in JNM: jnm.snmjournals.org/content/early/… Wonderful work from David Chen and team ProsTIC including James Buteau Declan Murphy

... how common is PSMA-negative significant prostate 
cancer? In the proPSMA study it was 3.3%

Hot of the press in <a href="/JournalofNucMed/">JNM</a>: jnm.snmjournals.org/content/early/…

Wonderful work from <a href="/davcmed/">David Chen</a> and team <a href="/pros_tic/">ProsTIC</a> including <a href="/ButeauJames/">James Buteau</a> <a href="/declangmurphy/">Declan Murphy</a>
Thomas Hope (@thomashopemd) 's Twitter Profile Photo

Exciting 177Lu-PSMA-617 has been approved by the FDA for use prior to chemotherapy based on the PSMAfore results. Perfect timing, during day 1 of the PSMA and Beyond Conference! bit.ly/42lfdlz

JNM (@journalofnucmed) 's Twitter Profile Photo

¹⁸F-FES PET is a successful biomarker for predicting the likelihood of success of endocrine therapy in patients with ER-positive #BreastCancer. ow.ly/WPMt50Vjv9Q #NuclearMedicine #PETscan Ashwin Singh Parihar, MBBS, MD

¹⁸F-FES PET is a successful biomarker for predicting the likelihood of success of endocrine therapy in patients with ER-positive #BreastCancer. ow.ly/WPMt50Vjv9Q

#NuclearMedicine #PETscan <a href="/TheNUCguy/">Ashwin Singh Parihar, MBBS, MD</a>
Michael Hofman (@drmhofman) 's Twitter Profile Photo

New Frontiers in PSMA Radioligand Therapy Is this the "hottest" session at ASCO #ASCO25 ?? ■ VIOLET: First-in-human trial of Terbium-161 ■ BULLSEYE: Lu-PSMA in oligo-metastatic disease ■ ENZA-p: Biomarkers ProsTIC PCF Science

New Frontiers in PSMA Radioligand Therapy

Is this the "hottest" session at <a href="/ASCO/">ASCO</a> #ASCO25  ??

■ VIOLET: First-in-human trial of Terbium-161
■ BULLSEYE: Lu-PSMA in oligo-metastatic disease
■ ENZA-p: Biomarkers

<a href="/pros_tic/">ProsTIC</a> <a href="/PCF_Science/">PCF Science</a>
Michael Hofman (@drmhofman) 's Twitter Profile Photo

Incredible prognostic power of PSMA PET from the updated PROMISE large international registry (PPP2): 3 and 5-yr survival data. Superior to NCCN risk score. Data across initial stage, biochemical recurrence, "non-metastatic" castration-resistant, mSPC, MCRPC !! Just out in

Incredible prognostic power of PSMA PET from the updated PROMISE large international registry (PPP2): 3 and 5-yr survival data. Superior to NCCN risk score. 

Data across initial stage, biochemical recurrence, "non-metastatic" castration-resistant, mSPC, MCRPC !!

Just out in
Michael Hofman (@drmhofman) 's Twitter Profile Photo

Stunning research from Edmond Kwan on ctDNA in theranostics: 🧬Low ctDNA predicts better response with ¹⁷⁷Lu-PSMA-617 vs. cabazitaxel chemotherapy ⚠️PTEN alterations linked to worse outcomes on cabazitaxel 🧪ATM defects tied to favorable PSMA-617 results 🩻PET quantitative

Stunning research from <a href="/EdmondMKwan/">Edmond Kwan</a> on ctDNA in theranostics:
🧬Low ctDNA predicts better response with ¹⁷⁷Lu-PSMA-617 vs. cabazitaxel chemotherapy
⚠️PTEN alterations linked to worse outcomes on cabazitaxel
🧪ATM defects tied to favorable PSMA-617 results
🩻PET quantitative
Michael Hofman (@drmhofman) 's Twitter Profile Photo

Getting ready for ASCO #ASCO25? ✈️🔬 There’s lots of theranostics … including a dedicated session for prostate cancer. Don’t miss these! 👀

Getting ready for <a href="/ASCO/">ASCO</a> #ASCO25? ✈️🔬

There’s lots of theranostics … including a dedicated session for prostate cancer. 

Don’t miss these! 👀
Michael Hofman (@drmhofman) 's Twitter Profile Photo

Pleased to share some first images of Lutetium-177 CA-IX peptide theranostics for metastatic clear cell renal cancer #ASCO25 ASCO. Ga-68 DPI-4452 PET/CT at baseline and on-treatment shown👇 State-of-the-Science: Novel Diagnostics and Therapeutics in Renal Cell Carcinoma

Toni Choueiri, MD (@drchoueiri) 's Twitter Profile Photo

📢 #ASCO25 | 3:00 PM–4:30 PM Clinical Science Symposium | Radioligand Therapy Remix: Finding the Right Patient for the Perfect Track | Jeremie Calais, MD, PhD dissects BULLSEYE (^177Lu‑PSMA‑617 in oHSPC), VIOLET (^161Tb‑PSMA‑I&T in mCRPC), and ENZA‑p (PSMA‑PET TTVol &

📢 #ASCO25 | 3:00 PM–4:30 PM Clinical Science Symposium | Radioligand Therapy Remix: Finding the Right Patient for the Perfect Track | Jeremie Calais, MD, PhD dissects BULLSEYE (^177Lu‑PSMA‑617 in oHSPC), VIOLET (^161Tb‑PSMA‑I&amp;T in mCRPC), and ENZA‑p (PSMA‑PET TTVol &amp;
Jeremie Calais (@calaisjeremie) 's Twitter Profile Photo

The UCLA Nuclear Medicine team is on the ground at #ASCO25 ! Every year, nuclear medicine & theranostics shine brighter on the #ASCO stage. UCLA UCLA Theranostics . #CancerResearch #NuclearMedicine #Theranostics

The UCLA Nuclear Medicine team is on the ground at #ASCO25 ! Every year, nuclear medicine &amp; theranostics shine brighter on the #ASCO stage.
<a href="/UCLA/">UCLA</a> <a href="/UCLATheranostic/">UCLA Theranostics</a> <a href="/UCLAJCCC/">.</a>
#CancerResearch #NuclearMedicine #Theranostics